Menu
Search
Home > Courses > Biomedical Prevention for COVID-19: Vaccines, MABs and Lessons from HIV

Biomedical Prevention for COVID-19: Vaccines, MABs and Lessons from HIV

Biomedical Prevention for COVID-19: Vaccines, MABs and Lessons from HIV
Play
Sorry, this learning module is not available for mobile devices.
Original Release Date: 7/22/2020
Termination Date: 07/21/2023
Review Date: 3/22/2021
Presenter
  • Mark J Mulligan, MD, FIDSA
    Director of the Division of Infectious Diseases & Immunology
    NYU Langone Vaccine Center
Presenter Bio
Mark Mulligan, MD, FIDSA
Mark J. Mulligan, MD, is the director of the Division of Infectious Diseases & Immunology in the Department of Medicine, and director of the NYU Langone Vaccine Center. He joined NYU Langone Health in 2018. He is a translational physician-scientist who leads a research clinic and a research laboratory. He conducts vaccine clinical trials and clinical studies of emerging infections. He has conducted research on HIV, Zika, Ebola, bird flu, 2009 pandemic influenza, and other vaccines and/or infections with public health impact. He is now studying the novel coronavirus. He is a graduate of the University of Notre Dame (cum laude, 1980), University of Texas Southwestern Medical School, Dallas (1984). During infectious diseases training (UAB, 1987-90) he did post-doctoral molecular virology training with Dr. Richard Compans, a renowned virologist. Dr. Mulligan served as multiple PI for an NIH-funded HIV/AIDS Clinical Trials Unit, conducting AIDS and TB research in Atlanta, Kenya, the Philippines, and Thailand (2006-2018). He also served as the principal investigator for an NIH-funded Vaccine and Treatment Evaluation Unit (VTEU), 2007-18. This was one of nine national units funded by NIH to conduct clinical research on medical countermeasures (such as vaccines, treatments, diagnostics, biomarkers) to combat infectious disease threats to human health. In 2020, the NYU Langone Vaccine Center received a seven-year grant from NIH/NIAID to become one of ten VTEUs currently awarded.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit on July 22, 2020 and will terminate July 21, 2023.


The target audience is all physicians, NPs and PAs involved or interested in HIV education.


This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

 Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.


The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) has no relevant financial relationships to disclose.
  • Dr. Valenti (Moderator) has no relevant financial relationships to disclose
  • Mark Mulligan, MD, FIDSA (Presenter) Dr. Mark Mulligan (Presenter) has had the following personal financial relationships in the past 12 months with manufacturers of the products or services that may be presented in this CME activity: Research support recipient from Lilly, and Pfizer. Dr. Mulligan will support his presentation and clinical recommendations with the best available evidence from the medical literature, and will submit his slides in advance for adequate peer review.  

This meeting of the Physicians’ Research Network (PRN) and enduring material were funded in part by educational grants from: Gilead Sciences, Janssen Therapeutics (a division of Janssen Products, LP), Merck & Co., and ViiV Healthcare.

Details: 

  • This online video and post-activity evaluation are one hour in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules